Navigation Links
OXiGENE Abstracts Published in ASCO Program

l M. Patterson of the Mount Vernon Cancer Centre indicates that while the study had not yet reached maximum tolerated dose and recruitment is ongoing, the data to date suggest that OXi4503 is tolerated at doses up to 5 mg/m2 without dose-limiting toxicity. Changes in functional activity, as assessed with DCI-MRI and PET imaging evaluations, were observed in three of the eleven patients studied. OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate is being evaluated in this Phase I dose escalation and safety study. Based on results to date, OXiGENE currently anticipates initiating further clinical studies with OXi4503 in 2007.

About Combretastatin A4 Phosphate/CA4P (ZYBRESTAT) and OXi4503

ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). The Company currently anticipates starting a Phase II/III pivotal registration study with ZYBRESTAT in June 2007 under a Special Protocol Assessment agreement with the US Food and Drug Administration. Via interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as substantial clinical activity against ATC and other solid tumors in clinical studies to date. Our strategy for optimizing the antitumor activity of ZYBRESTAT is to combine it with other types of therapeutic modalities, including cytotoxic drugs, anti-angiogenesis drugs, and radiation therapy. The rationale for combining ZYBRESTAT with other therapeutic modalities stems from the hypothesis that agents with different and potentially complimentary mechanisms of action and with a non-overlapping toxicity profile may achi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:9/4/2015)... is pleased to announce the launch of Eyezen ™ ... comes with the constant connection to digital devices. Eyezen ... of glasses to provide comfort and protection for a ... and computers for hours at a time. Eyezen glasses ... also those who currently wear contact lenses or do ...
(Date:9/4/2015)... 4, 2015  PTC Therapeutics, Inc. (NASDAQ: ... of its first-ever global awards program, the STRIVE ... designed to aid nonprofit organizations that are committed ... The announcement is made as the global DMD ... Day on Monday, September 7, 2015. ...
(Date:9/4/2015)... , Sept. 4, 2015  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA) of ... submissions now pending at the FDA to twenty-nine. ... the Company, commented, "We believe our current pipeline of ...
Breaking Medicine Technology:Essilor Launches New Eyezen Glasses Specifically Designed For A Digital Focused Audience 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2
... REDWOOD CITY, Calif., March 19, 2012 Ingenuity Systems, ... life science researchers, today announced that the Weill Cornell ... iReport for use in its sequencing core facility.  Variant ... the output of whole genome and exome sequencing experiments ...
... 19, 2012  Johnson & Johnson (NYSE: JNJ) will provide ... parties on Monday, March 26th at approximately 10:30 ... College of Cardiology (ACC) Annual Scientific Sessions in ... of the EINSTEIN-PE study in treating patients with ...
Cached Medicine Technology:Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and ... rules constantly evolving in the consumer goods industry, it can be difficult for ...
(Date:9/4/2015)... ... September 04, 2015 , ... San ... available at CitiDent. CEREC is a newer method for creating restorations through innovative ... patients by eliminating the need for multiple appointments, CEREC produces restorations with total ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a fresh ... its only mission and research focus: Water Life Science®. In the current warming ... evaporation is becoming dangerously accelerated. As a result of the global fresh water, ...
(Date:9/4/2015)... ... September 04, 2015 , ... ECC announces ... neighborhood created specifically for adults with intellectual, developmental and acquired disabilities. The first ... feature 30 cottage or “pocket” homes. In this community, adults will live safely ...
(Date:9/4/2015)... ... 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written an ... Pope’s upcoming trip to the United States. , Yisrayl lays out what he says is ... and society is. Yisrayl also provides the meaning of his own name and describes what ...
Breaking Medicine News(10 mins):Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... A patients expectations about the side effects of ... other side effects. Worries about severe allergic reactions to ... recent study from the Lineberger Comprehensive Cancer Center at ... Vanderbilt-Ingram Comprehensive Cancer Center and the Sarah Canon Cancer ...
... report says , MONDAY, Aug. 20 (HealthDay News) -- ... not used often enough in the United States, says ... diagnosed with COPD ever received the testing. , ... accepted and encouraged method of diagnosing COPD. ...
... to men of other ethnicities, Tulane University researchers found ... may increase the risk of stroke in Chinese men. ... latest issue of Annals of Neurology. ... School of Public Health and Tropical Medicine recently examined ...
... ethnicities, researchers say , MONDAY, Aug. 20 (HealthDay News) ... men, a new study finds. , The researchers looked of ... history of stroke when first surveyed in 1991. , When ... 2000, researchers found there had been 3,434 strokes and ...
... cardioverter defibrillators (ICDs) are safe and significantly reduce ... (Review, p. 251). In this review of eight ... 76 observational studies that examined safety or effectiveness, ... with left ventricular systolic dysfunction by 20 percent. ...
... in 5 report symptoms of anxiety, depression once back home ... major symptom of post-traumatic stress disorder (PTSD) was reported by ... Force deployed during the Iraq War, says a University of ... conflict. , The women in the survey (74.2 percent enlisted, ...
Cached Medicine News:Health News:Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US 2Health News:Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US 3Health News:Heavy Drinking Boosts Stroke Risk for Chinese Men 2Health News:Work-Family Conflict Dogs Air Force Women After Deployment 2
... The Biomet Ankle ... ideally suited for,tibiotalocalcaneal ... second-generation nail affords ... fixation that incorporates ...
... clinical and economic issues of cerclage wiring, ... to maximize tension control while minimizing invasion ... efficient instrumentation with a simple technique. , ... indicated for general orthopaedic trauma surgery involving: ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... of DePuy's aggressive innovations have become the ... be equalled. The AML Total Hip ... efficiently address and effectively meet the needs ... With greater than 15 years of ...
Medicine Products: